Piper Jaffary "NEAR TERM for SRPT $60-$80 AFTER APPROVAL $160" link
Piper Jaffary "NEAR TERM for SRPT $60-$80 AFTER APPROVAL $160 " **link**
Sarepta Therapeutics (SRPT) Jumps on Bullish CommentS
November 21, 2012 9:18 AM EST
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is seeing strong pre-open action following positive comments from analysts at Piper Jaffray. The firm said it has the potential to be a $160/share stock but a nearer-term range could be $60-$80/share.
Based on the size of the market, especially with the ANCHOR indication in hand, if AMRN GIA, it will be a $100+++ stock.
SRPT has a great and much needed product that's going to be approved soon, but the market is not even close to the size of the market Vascepa will be competing in.